1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
IMV Inc.

IMV Inc.

IMVIF
IMV Inc.US flagOther OTC
0.00
USD
- -
- -
23,423.00Market Cap
IMV Inc.
IMVIF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
0.02
0.05
- -
- -
- -
- -
0.03
0.03
0.01
0.01
0.01
- -
- -
- -
- -
Revenue per Share
-0.23
-0.03
-0.16
-3.79
-3.95
-3.33
-2.05
-2.17
-2.2
-2.09
-2.47
-3.68
-4.22
-4.32
-4.93
-4.55
-4.62
Basic EPS, GAAP
-0.14
-0.07
-0.19
-3.17
-3.15
-2.96
-2.09
-1.63
-1.8
-1.45
-1.93
-3.26
-4.28
-3.91
-4.51
-4.13
-4.19
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.23
-0.17
-0.33
-11.16
0.75
-1.26
-0.63
0.71
-1.58
-0.15
-0.15
-0.44
-0.4
3.05
0.18
-4.17
-4.23
Book Value per Share
1.73
1.54
1.3
7.28
2.73
0.78
1.01
2.51
-0.03
1.64
1.3
0.72
1
5.11
2.9
-0.79
-0.8
Tangible Book Value per Share
- -
- -
- -
1
2
2
2
3
3
3
4
4
5
6
7
8
8
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
-892.58
-7,321.7
- -
- -
- -
- -
-6,455.93
-5,608.45
-34,090.91
-25,550
-45,144.07
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
Depreciation Expense
- -
- -
- -
-6
-7
-6
-4
-6
-6
-7
-10
-16
-21
-26
-37
-38
-38
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-892.58
-7,428.92
- -
- -
- -
- -
-6,765.39
-6,858.61
-36,445.45
-26,750
-46,381.36
- -
- -
- -
- -
Profit Margin (%)
- -
1
- -
11
5
2
3
9
2
10
11
9
10
36
37
18
18
Working Capital
- -
- -
- -
1
1
1
1
3
3
5
5
7
7
7
19
29
29
LT Debt
- -
1
- -
11
5
2
2
7
- -
5
5
3
5
31
22
-7
-7
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-371.65
- -
-628.95
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'22
Sep'22
Dec'22
ST Debt
- -
- -
- -
LT Borrowings
28
27
27
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
10
Market Capitalization
53
43
20

Working Capital

FRC

•

in mil. unless spec.
Jun'22
Sep'22
Dec'22
Total Current Assets
36
28
28
Cash, Cash Equivalents & STI
31
22
21
Accounts Receivable, Net
1
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
9
10
9
Payables & Accruals
8
10
9
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,078.35%
76.08%
-130.65%
Free Cash Flow
24.24%
39.19%
3.06%
Net Income, GAAP
22.51%
33.42%
3.83%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
-1.42
-0.92
-0.95
- -
-4.32
2021
-1.03
-1.1
-1.32
- -
-4.93
2022
-1.28
-1.2
-1.08
- -
-4.55

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Similar Companies
Eupraxia Pharmaceuticals Inc. (EPRXF)
Alfavision Overseas (India) Limited (ALFAVIO.BO)
Doseology Sciences Inc. (DOSEF)
Mesoblast Limited (MSB.AX)
Lin BioScience, Inc. (6696.TWO)
Simcere Pharmaceutical Group Limited (2096.HK)
Business
IMV Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of immunotherapies aimed at treating cancer and infectious diseases. Its core products and services include proprietary drug candidates based on the DPX platform technology, encompassing immuno-oncology therapies, cancer vaccines, and immunotherapies targeting lymphoma and solid tumors. IMV’s lead product candidates include treatments for ovarian cancer, diffuse large B-cell lymphoma (DLBCL), and other solid tumor indications. The company also engages in collaborations to develop immunotherapies for infectious diseases leveraging its technology platform. IMV operates primarily in North America, with its headquarters located in Dartmouth, Nova Scotia, Canada. Founded in 2004, the company serves the pharmaceutical and biotech industries, focusing on innovative therapies that activate the immune system to fight cancer and infections. Recent major developments at IMV include strategic partnerships to expand its immunotherapy pipeline and enhance its clinical development programs. In the last 1-2 years, IMV has launched new clinical trials for its lead candidates, entered licensing agreements to access complementary technology platforms, and has undergone operational expansions to support rapid clinical growth. Additionally, IMV continues to invest in the advancement of its DPX delivery platform technology, improving the efficacy and safety of its drug candidates. There has been no recent change in the company’s name or major restructuring reported. IMV’s comprehensive business segments cover research and development of next-generation immunotherapies, clinical trial execution, and technology licensing. Its target markets include oncology patients, healthcare providers, and pharmaceutical collaborators in Canada, the United States, and potentially global markets through partnerships and licensing agreements. The company’s scientific and operational capabilities position it as a specialized player in the immuno-oncology and infectious disease treatment domains.